Vitiligo

OPZELURA Cream for Vitiligo: Efficacy, Side Effects, and Price

OPZELURA cream (ruxolitinib 1.5%) is a topical JAK inhibitor and the first targeted therapy approved worldwide for vitiligo. In two phase 3 trials involving 674 patients aged 12 and older with nonsegmental vitiligo, about 30% achieved at least 75% improvement in facial vitiligo scores after 24 weeks, and about half after 52 weeks. In the U.S., a 60 g tube costs $2,094 (approximately 3 million KRW). As of November 2, 2026, it has not yet been launched in Korea.

What Is OPZELURA Cream for Vitiligo?

OPZELURA cream (ruxolitinib 1.5%) is a topical JAK inhibitor and the first targeted therapy approved for vitiligo. It was authorized for nonsegmental vitiligo in patients aged 12 and older in the U.S. in July 2022 and in Europe in April 2023.

Vitiligo is an autoimmune disease in which T cells attack melanocytes. When T cells that have accumulated in the skin release interferon-gamma, nearby skin cells produce chemokines such as CXCL10 via intracellular JAK signaling, and these chemokines recruit more T cells to the skin. Applying OPZELURA inhibits JAK1 and JAK2 at the site, reducing chemokine production and weakening the immune attack on melanocytes. However, in older lesions where melanocytes have been completely lost, immune modulation alone may not be sufficient to restore pigment.


How Effective Is OPZELURA Cream for Vitiligo?

In two phase 3 trials (TRuE-V1 and TRuE-V2) involving 674 patients aged 12 and older with nonsegmental vitiligo, about 30% of those who applied OPZELURA for 24 weeks achieved at least 75% improvement in facial vitiligo scores. In the placebo group, about 10% achieved this. After 52 weeks of continuous OPZELURA use, the proportion rose to about half (50.3%).

Participants had vitiligo covering 10% or less of their body surface area. They applied OPZELURA cream or placebo to white patches on the face and body twice daily for 24 weeks, after which all participants switched to OPZELURA for up to 52 weeks. A 75% or greater improvement in facial vitiligo score (F-VASI75) means the total area of facial lesions decreased by at least 75% compared to before treatment.

24-week results (F-VASI75)TRuE-V1TRuE-V2
OPZELURA cream29.8%30.9%
Placebo7.4%11.4%

When assessed across the whole body, fewer than one in ten patients achieved that level of improvement after six months of application.


How Long Should You Use OPZELURA Cream, and Does Vitiligo Return After Stopping?

To achieve satisfactory results with OPZELURA cream, you need to apply it consistently for at least 6 to 12 months. Patients who stopped treatment experienced significantly more recurrence of vitiligo compared to those who continued.

Improvement continued beyond one year. Among patients who applied OPZELURA from the start and had not yet achieved 90% facial repigmentation at week 52, those who continued for another year saw the proportion with at least 75% improvement rise from one in three to two in three.

In a separate study, patients who had achieved 90% or more facial repigmentation after one year were split into two groups: one continued OPZELURA, and the other switched to placebo for another year. Six in ten maintained that state in the OPZELURA group, compared to two in ten in the placebo group. However, among those who worsened on placebo, three out of four regained at least 75% improvement within about three months after restarting OPZELURA.


Which Type of Vitiligo Can OPZELURA Cream Be Used For?

OPZELURA cream is approved for nonsegmental vitiligo in patients aged 12 and older, and it is authorized for application to up to 10% of the body surface area. Since one hand (including fingers) is roughly 1% of body surface area, the limit is about the area of ten hands. Therefore, it may not be suitable for widespread vitiligo on the back, abdomen, or limbs. Because clinical trials only included nonsegmental vitiligo, it is not yet clear whether the same effect occurs in segmental vitiligo.

The best response is seen on the face. Areas with fewer hair follicles, such as the hands and feet, tend to respond less, as is the case with other treatments. This is because new melanocytes to replace lost ones mostly come from melanocyte stem cells deep in the hair follicles. If the hair within a white patch has also turned white (leukotrichia), it suggests these stem cells are depleted, and the area may respond poorly to UV therapy or medication; surgery may be considered in such cases.

Several clinical studies have shown that combining a JAK inhibitor with UV therapy, which helps melanocytes migrate and proliferate, yields better results. Since OPZELURA suppresses the immune response against melanocytes, it is not considered a complete replacement for existing treatments such as UV therapy or surgery, which help replenish lost melanocytes.


What Are the Side Effects of OPZELURA Cream?

The most common side effects of OPZELURA cream are acne and itching at the application site, occurring in about 6% and 5% of patients, respectively, over 52 weeks of use. Cold symptoms of the nose and throat (nasopharyngitis) were also similarly common.

An analysis of safety data collected over two years (104 weeks) found no serious adverse events related to treatment. Malignancies, serious infections, and blood clots were rare and all judged unrelated to treatment. No major cardiovascular events or deaths occurred.


Can I Get OPZELURA Cream in Korea? How Much Does It Cost?

As of November 2, 2026, OPZELURA cream has not been approved by the Ministry of Food and Drug Safety, so it is not available or prescribable in Korea. In the United States, a 60 g tube is prescribed at $2,094, which is about 3 million won.

The only targeted treatment for vitiligo currently prescribable in Korea is Rinvoq, an oral JAK inhibitor. It was approved in October 2026 for nonsegmental vitiligo in patients aged 12 and older. Because it is taken orally, unlike OPZELURA, there is no limit on the area you can treat, and it can be used for widespread vitiligo.


Which is better for vitiligo: OPZELURA or Protopic?

When comparing results from separate clinical trials, the two medications appear to have similar efficacy for facial vitiligo. After 24 weeks, about 30% of patients using OPZELURA cream achieved at least a 75% improvement in facial vitiligo scores. Similarly, when Protopic ointment was applied to lesions on the face and neck, roughly one in three patients saw 75% or greater repigmentation. However, head-to-head studies comparing the two under the same conditions are still limited, so it is difficult to conclude that one is superior to the other.

Since OPZELURA is not yet available for prescription, applying Protopic ointment consistently to facial vitiligo is a realistic option, and the difference in outcomes may not be significant. Protopic is covered by health insurance for vitiligo on the face and neck, does not thin the skin, so it can be used long-term, and combining it with UV therapy such as excimer laser can improve results.

Although OPZELURA is not yet available in Korea, the face is an area that can improve with existing treatments.


References

  • Rosmarin D, et al. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022.

  • Seneschal J, et al. Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Characteristic Subgroups: Descriptive Pooled Analysis From Two Phase 3 Studies. Dermatol Ther. 2025.

Jung Min Bae, board-certified dermatologist — Gangnam Branch

Jung Min Bae

Dermatologist · Gangnam Branch

With sincere care and continuous research, I will be a reliable companion for vitiligo patients.


Request Consultation

View

WhatsApp

WhatsApp chat is for our Gangnam Branch. For other branches, please use Quick Consultation.

WhatsApp

Country code